We found that a combination of an early recombinant IFN‐α/β injection at 18 h p.i. with an administration of anti‐IL‐6R antibodies at day three p.i. could reduce parasitemia and prolong mouse survival (Figure 3A,B). Here, IL6R is linked to parasitic infectious disease.